Format

Send to

Choose Destination
Curr Opin Chem Biol. 2013 Jun;17(3):393-9. doi: 10.1016/j.cbpa.2013.03.023. Epub 2013 Apr 6.

Bispecific antibodies for delivery into the brain.

Author information

1
Neurodegeneration Labs, Department of Neuroscience, Genentech, Inc., 1 DNA Way, South San Francisco, United States.

Abstract

The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis. Therapeutics designed to take advantage of this approach require at least two functionalities, one that facilitates transport and the other to provide therapeutic benefit, and bispecific antibodies are ideally suited for this task.

PMID:
23570979
DOI:
10.1016/j.cbpa.2013.03.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center